Quantcast

Latest Carbidopa Stories

2014-09-03 12:30:29

Continuous levodopa therapy with ND0612H has the potential to prevent or delay the need for surgical intervention in patients with severe stage Parkinson's disease REHOVOT, Israel, September 3, 2014 /PRNewswire/ -- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the first patients with severe Parkinson's disease have been enrolled and dosed in a Phase IIa trial of ND0612H. ND0612H is a...

2014-08-21 16:24:23

REHOVOT, Israel, August 21, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group. The company plans to use the funding to further the clinical and regulatory...

2014-08-04 08:27:58

REHOVOT, Israel, August 4, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). According to EMA guidelines, the EMA can allow products for which the centralized...

2014-04-11 08:24:24

HAYWARD, Calif., April 11, 2014 /PRNewswire/ -- Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA). IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug for the symptomatic treatment of Parkinson's disease (PD). After discussions with the FDA, the Company has...

2014-04-10 08:28:50

DUODOPA improves quality of life for those with advanced stages of disease MONTREAL, April 10, 2014 /CNW/ - AbbVie today announced that a new treatment called DUODOPA(® )(levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Currently, more than 100,000 Canadians live with Parkinson's - a progressive, incurable neurological disorder that can significantly affect the quality of life of patients, their families and caregivers. DUODOPA is approved...

2014-03-11 08:29:26

REHOVOT, Israel, March 11, 2014 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease....


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related